Dr. Ruan on the Utility of Molecular Profiling in Mantle Cell Lymphoma

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses ​the utility of molecular profiling in mantle cell lymphoma (MCL).

Obtaining a patient's genetic mutation profile can be a useful risk-stratification tool, says Ruan. For example, TP53 mutations or deletions can inform a patient’s prognosis and likelihood of response to standard therapy.

Prospective studies using chemoimmunotherapy ​demonstrated​ less favorable survival data for patients with TP53 aberrations compared with patients who do not harbor TP53 aberrations, explains Ruan. Although chemoimmunotherapy may be offered to these patients, ​alternative options should be considered ​early on in cases of no response or early relapse.